Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPDNHLBI/WHO workshop reportBethesda, MDNational Heart, Lung and Blood Institute42001 NIH Publication. No 27011100 Last updated 2014. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.htmlAccessed January 27, 2014
   Google Scholar
• QaseemAWiltTJWeinbergerSEAmerican College of PhysiciansAmerican College of Chest PhysiciansAmerican Thoracic SocietyEuropean Respiratory SocietyDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med201115517919121810710
   PubMed Web of Science ®Google Scholar
• AppletonSPoolePSmithBVealeALassersonTJChanMMLong-acting beta-agonists for poorly reversible chronic obstructive pulmonary diseaseCochrane Database Syst Rev20063CD00110416855959
   PubMed Web of Science ®Google Scholar
• ChongJKarnerCPoolePTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD00915722972134
   PubMed Web of Science ®Google Scholar
• YangIAClarkeMSSimEHFongKMInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00299122786484
   PubMed Web of Science ®Google Scholar
• SpencerSKarnerCCatesCJEvansDJInhaled corticosteroids versus long-acting beta-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201112CD007033
   Web of Science ®Google Scholar
• YawnBPLiYTianHZhangJArconaSKahlerKHInhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysisInt J Chron Obstruct Pulmon Dis2013829530423836970
   PubMed Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJHolmesRNormansellRCombined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD00379424214176
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
   PubMed Web of Science ®Google Scholar
• KliberALyndLDSinDDThe effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary diseaseRespir Res2010115620459831
   PubMed Web of Science ®Google Scholar
• DongYHLinHHShauWYWuYCChangCHLaiMSComparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trialsThorax201368485623042705
   PubMed Web of Science ®Google Scholar
• CyrMCBeauchesneMFLemièreCAaronSDBlaisLEffects of inhaled corticosteroids in monotherapy or combined with long-acting β2-agonists on mortality among patients with chronic obstructive pulmonary diseaseAnn Pharmacother20104461362220233915
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev20126445050422611179
   PubMed Web of Science ®Google Scholar
• CazzolaMRoglianiPSegretiAMateraMGAn update on bronchodilators in Phase I and II clinical trialsExpert Opin Investig Drugs20122114891501
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPRoglianiPMateraMGβ2-agonist therapy in lung diseaseAm J Respir Crit Care Med201318769069623348973
   PubMed Web of Science ®Google Scholar
• RossiAPoleseGIndacaterol: a comprehensive reviewInt J Chron Obstruct Pulmon Dis2013835336323922496
   PubMed Web of Science ®Google Scholar
• SpinaDCurrent and novel bronchodilators in respiratory diseaseCurr Opin Pulm Med201420738624247039
   PubMed Web of Science ®Google Scholar
• AdcockIMCaramoriGKirkhamPAStrategies for improving the efficacy and therapeutic ratio of glucocorticoidsCurr Opin Pharmacol20121224625122445282
   PubMed Web of Science ®Google Scholar
• GoldenbergMMPharmaceutical approval updatePharmacy and Therapeutics20133838940324049424
   PubMedGoogle Scholar
• http://www.ema.europa.eu [homepage on the Internet]Accessed January 27, 2014
   Google Scholar
• CaramoriGAdcockIMPharmacology of airway inflammation in asthma and COPDPulm Pharmacol Ther20031624727712877818
   PubMed Web of Science ®Google Scholar
• CaramoriGCasolariPAdcockIRole of transcription factors in the pathogenesis of asthma and COPDCell Commun Adhes201320214023472830
   PubMed Web of Science ®Google Scholar
• RamamoorthySCidlowskiJAExploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistanceEndocr Dev201324415623392094
   PubMedGoogle Scholar
• OakleyRHCidlowskiJAThe biology of the glucocorticoid receptor: new signaling mechanisms in health and diseaseJ Allergy Clin Immunol20131321033104424084075
   PubMed Web of Science ®Google Scholar
• SalterMBiggadikeKMatthewsJLPharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory diseaseAm J Physiol Lung Cell Mol Physiol2007293L660L66717575011
   PubMed Web of Science ®Google Scholar
• BiggadikeKBledsoeRKHassellAMX-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domainJ Med Chem2008513349335218522385
   PubMed Web of Science ®Google Scholar
• ValotisAHöggerPHuman receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoateRespir Res200785417650349
   PubMed Web of Science ®Google Scholar
• RossiosCToYToMLong-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cellsEur J Pharmacol201167024425121920359
   PubMed Web of Science ®Google Scholar
• AllenABalJCheesbroughAHamiltonMKempsfordRPharmacokinetics (PK) and pharmacodynamics (PD) of intravenous and inhaled fluticasone furoate (FF) in healthy Caucasian and East Asian subjectsBr J Clin Pharmacol Epub10242013
   Google Scholar
• AllenABareillePJRousellVMFluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionateClin Pharmacokinet201352374223184737
   PubMed Web of Science ®Google Scholar
• JohnsonMRennardSAlternative mechanisms for long-acting β2-adrenergic agonists in COPDChest200112025827011451847
   PubMed Web of Science ®Google Scholar
• BarnesPJDistribution of receptor targets in the lungProc Am Thorac Soc2004134535116113456
   PubMedGoogle Scholar
• ChungKFCaramoriGAdcockIMInhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and futureEur J Clin Pharmacol20096585387119557399
   PubMed Web of Science ®Google Scholar
• HaqueRHakimAMoodleyTInhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPDJ Allergy Clin Immunol20131321166117324070494
   PubMed Web of Science ®Google Scholar
• RothMJohnsonPRRüdigerJJInteraction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signallingLancet20023601293129912414205
   PubMed Web of Science ®Google Scholar
• ProcopiouPABarrettVJBevanNJSynthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approachJ Med Chem2010534522453020462258
   PubMed Web of Science ®Google Scholar
• SlackRJBarrettVJMorrisonVSIn vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of actionJ Pharmacol Exp Ther201334421823023131596
   PubMed Web of Science ®Google Scholar
• HananiaNASharafkhanehABarberRDickeyBFBeta-agonist intrinsic efficacy: measurement and clinical significanceAm J Respir Crit Care Med20021651353135812016095
   PubMed Web of Science ®Google Scholar
• HananiaNAFeldmanGZachgoWThe efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialChest201214211912722241764
   PubMed Web of Science ®Google Scholar
• KempsfordRNorrisVSiedererSVilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPDPulm Pharmacol Ther20132625626423232038
   PubMed Web of Science ®Google Scholar
• SterlingRLimJFrithLSnowiseNGJacquesLHaumannBEfficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: a randomised trialRespir Med20121061110111522520084
   PubMed Web of Science ®Google Scholar
• KumarRKumarDParakhAFluticasone furoate: a new intranasal corticosteroidJ Postgrad Med201258798322387656
   PubMed Web of Science ®Google Scholar
• KempsfordRAllenABalJRubinDTombsLThe effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjectsBr J Clin Pharmacol2013751478148723116485
   PubMed Web of Science ®Google Scholar
• AllenAThe relationship between fluticasone furoate systemic exposure and cortisol suppressionClin Pharmacokinet20135288589623719680
   PubMed Web of Science ®Google Scholar
• AllenADavisAHardesKTombsLKempsfordRInfluence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combinationClin Ther2012342316233223200625
   PubMed Web of Science ®Google Scholar
• BosciaJAPudiKKZvarichMTSanfordLSiedererSKCrimCEffect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover studyClin Ther2012341655166622789766
   PubMed Web of Science ®Google Scholar
• LötvallJBakkePSBjermerLEfficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trialBMJ Open20122e000370
   PubMed Web of Science ®Google Scholar
• AgustíAde TeresaLDe BackerWA comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPDEur Respir J Epub10102013
   Web of Science ®Google Scholar
• BollmeierSGProsserTRCombination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary diseaseAnn Pharmacother Epub11192013
   Web of Science ®Google Scholar
• KerwinEMScott-WilsonCSanfordLA randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPDRespir Med201310756056923352226
   PubMed Web of Science ®Google Scholar
• MartinezFJBosciaJFeldmanGFluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trialRespir Med201310755055923332861
   PubMed Web of Science ®Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med2013121022324429127
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJBrookRDThe Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocolEur Respir J2013411017102223018908
   PubMed Web of Science ®Google Scholar
• SvedsaterHDalePGarrillKWalkerRWoepseMWQualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPDBMC Pulm Med2013137224314123
   PubMed Web of Science ®Google Scholar
• KelleherDLMehtaRSJean-FrancoisBMSafety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trialPLoS One20127e5071623284643
   PubMed Web of Science ®Google Scholar
• KempsfordRAllenAKellyKSagguPCrimCA repeat-dose thorough QT study of inhaled fluticasone furoate (FF)/vilanterol (VI) combination in healthy subjectsBr J Clin Pharmacol Epub1042013
   Web of Science ®Google Scholar
• NakaharaNWakamatsuAKempsfordRThe safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjectsInt J Clin Pharmacol Ther20135166067123735179
   PubMed Web of Science ®Google Scholar
• HussarDAAhmadAVilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodiumJ Am Pharm Assoc201353662670
   Google Scholar
• FromerLBarnesTGarveyCOrtizGSaverDFYawnBInnovations to achieve excellence in COPD diagnosis and treatment in primary carePostgrad Med201012215016420861599
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJACalverleyPMAdherence to inhaled therapy, mortality and hospital admission in COPDThorax20096493994319703830
   PubMed Web of Science ®Google Scholar
• Simoni-WastilaLWeiYJQianJAssociation of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare populationAm J Geriatr Pharmacother20121020121022521808
   PubMed Web of Science ®Google Scholar
• ÁghTInotaiAMészárosÁFactors associated with medication adherence in patients with chronic obstructive pulmonary diseaseRespiration20118232833421454953
   PubMed Web of Science ®Google Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax20086383183818728206
   PubMed Web of Science ®Google Scholar